We have not explained this story yet. The original headline, summary and link are below.

This Form 4 filing details insider transactions for BELITE BIO, INC (BLTE) by Chief Medical Officer Scholl Hendrik Peter. The report indicates multiple sales of American depositary shares on October 1, 2026, executed under a Rule 10b5-1 trading plan. These transactions involved a total of 500 shares at varying weighted average prices, leaving the reporting person with 14,500 shares beneficially owned indirectly through Bioptima Ltd.